SAN DIEGO, Dec 18, 2008 /PRNewswire-FirstCall via COMTEX/ -- SpectraScience, Inc., a San Diego based medical device company, today commented on the recent media coverage of a Canadian study which shows the limitations of colonoscopies in detecting cancer. The study reports that the procedure may detect polyps and early cancerous tissue only 60 to 70 percent of the time. SpectraScience announced today that the significant rate of missed cancers during colonoscopies may be greatly improved by the use of the Company’s WavSTAT(R) Optical Biopsy System.
